Antares Therapeutics tackles brand-new protein pockets

Antares Therapeutics secured $177 million in Series A funding to develop small-molecule drugs targeting novel protein pockets, founded by former Scorpion Therapeutics executives after Eli Lilly acquired their previous firm's lead asset.